Objective: To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD).
O ur limited ability to help the 30 million people worldwide who suffer from dementia [1] [2] [3] [4] is made all the more frustrating by the currently available drugs, which treat symptoms of cognitive decline but do little to reverse it. 2, 3 Patients with Alzheimer disease (AD), the most common form of dementia, suffer not only a decrease in brain cholinergic activity, 2,3 but also a glutamatergic excitotoxicity that leads to loss of synaptic plasticity and neuronal death, manifesting as loss of ability to learn and remember. 2, 3 Treating AD with acetylcholinesterase inhibitors compensates for the decrease in brain cholinergic activity by keeping higher levels of acetylcholine in synapses, but these drugs do not alter the pathogenesis. 2, 3 By contrast, treating AD with memantine may improve symptoms by restoring plasticity and may delay neuronal death by limiting glutamatergic toxicity. Memantine acts as a non-competitive, low-affinity, voltage-dependent modulator of glutamatergic N-methyl-D-aspartate (NMDA) receptors. [5] [6] [7] Its effectiveness in patients with moderate to severe AD has been shown in randomized controlled trials: patients who had been taking memantine for 6 months reported better cognitive performance than did patients taking a placebo. [5] [6] [7] [8] Nevertheless, the real medico-economic impact of memantine continues to be debated, because the improvement in cognitive score, even if statistically significant, 8 is not clinically relevant. On the 70-point Alzheimer's Disease Assessment Scale-Cognition, patients taking memantine had a mean improvement of 1.25 ± 5.32 points at 28 weeks. 8 However, the therapeutic success of anti-dementia drugs is defined as an improvement of at least 3 points. 9, 10 Improving clinical outcomes will require multitarget regimens to combine memantine with complementary molecules to better protect neurons and prevent AD from worsening. [11] [12] [13] Among the candidates is vitamin D, a neurosteroid hormone with neurotrophic, anti-inflammatory, anti-oxidant, and anti-ischemic neuroprotective properties. [13] [14] [15] [16] [17] [18] [19] We wondered whether combining memantine with vitamin D might be effective against numerous degenerative processes at once. 13 Our objective in this study was to determine whether memantine plus vitamin D could be more effective than memantine or vitamin D alone in improving global cognitive performance in patients with AD.
METHODS

Study Population
We collected data retrospectively from the patient database of the Memory Clinic of Angers University Hospital, France. To be included in the study, a patient had to: make an initial outpatient visit to the Memory Clinic between July 2009 and February 2010, and at least 1 follow-up outpatient visit have a new diagnosis of AD not have delirium have a prescription for memantine and/or vitamin D supplements, for any reason not have a co-prescription for a cerebral vasodilator or for an acetylcholinesterase inhibitor such as donepezil, galantamine, or rivastigmine
The 43 patients who met these criteria were included in the analysis. Their clinical characteristics are summarized in Table 1 . The Memory Clinic had diagnosed their AD according to the criteria of the US National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) work group. 20 The Clinic had used the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV ) criteria to establish the clinical diagnosis of dementia of any duration or stage, without delirium. 21 We learned about the patients' medications by asking them and by checking the primary care physician's prescription.
Between-visit Change in Cognitive Performance
Our Memory Clinic uses, among other tests, the Mini-Mental State Examination (MMSE) 22 to assess patients' global cognitive performance at every visit. The test is given by a neuropsychologist who has no knowledge of the patients' treatment status. Thus, our Clinic database included MMSE scores for all of our study patients, both at baseline (before they were given their drug prescription) and at their first follow-up visit. The MMSE is a well-established measure of 5 areas of cognitive function: orientation, registration, attention-calculation, recall, and language. The MMSE shows good test-retest and inter-rater reliability, and compares sat-isfactorily with more detailed measures of cognitive function. 22 Scores range from 0 (severely impaired) to 30 (normal). Scores must rise by at least 2 points to be considered clinically relevant improvement. 23, 24 Treatment On the day of their first clinic visit (their date of inclusion in the study), the patients received their first prescription for memantine, vitamin D supplements, or both. To improve adherence to treatment, a home-visiting nurse dispensed the drugs daily to the non-autonomous patients. 25 Memantine was given orally, titrated in 5 mg increments over 4 weeks up to a full dose of 20 mg/day. Most patients took a single dose in the morning. For those with severe renal insufficiency, the dose was divided by 2, as recommended in the summary of product characteristics.
Vitamin D supplements were given orally, either daily or monthly. The dose ranged between 400 and 1000 IU per day, or 100,000 and 200,000 IU per month. We considered all prescriptions of vitamin D supplements in this analysis, regardless of the indication. Of note, because about 90% of older adults in France have vitamin D deficiency, 26 some of our patients received vitamin D supplements without having their serum 25-hydroxyvitamin D concentration tested. 27 Moreover, in the group treated only with vitamin D supplements, the 6-month prescription corresponded generally to the length of time needed to test and qualify patients for AD-specific treatment.
Statistical Analysis
Having 43 participants, we were allowed to adjust for up to 4 covariables in multivariate analyses (1 variable per 10 participants). As potential confounders, we used age, sex, baseline (pre-treatment) MMSE score, and years between the 2 visits (ie, duration of treatment). Because the rate of vitamin D skin synthesis (the main natural source of vitamin D) depends on sun exposure and season, 26 we also noted the season of the year when patients started treatment: spring from March 21 to June 20, summer from June 21 to September 20, autumn from September 21 to December 20, and winter from December 21 to March 20.
We divided the patients into 3 groups, 1 for each treatment (memantine alone, vitamin D alone, or memantine plus vitamin D), and compared the groups using the w 2 test or the Kruskal-Wallis test. To address the problem of multiple comparisons, we did a Bonferroni test. We also used the Wilcoxon signed-ranks test to assess the change in MMSE score after treatment within each group.
We performed univariate and multiple linear regression analyses to examine the association between the MMSE score change (dependent variable) and the treatment effect (independent variable, with the group taking memantine plus vitamin D as the reference group). We performed linear regression model 1 without any adjustments, model 2 after adjusting for baseline MMSE score, and model 3 after adjusting for all clinical characteristics.
Finally, we performed a mixed regression model (with the Stata xtmixed command, StataCorp., College Station, TX), taking into account the exact time between the 2 MMSE tests. We considered treatment effect, initial and follow-up visits, age, sex, and treatment effect by visit interaction as fixed effects. We considered participants and time as random effects.
We considered P-values <0.05 to be statistically significant. We performed all statistical analyses using SPSS (Version 19.0; SPSS Inc., Chicago, IL) and Stata (Version 12.1; Stata Corp.).
Standard Protocol Approvals, Registrations, and Patient Consents
All outpatients followed at the Angers University Memory Clinic are asked whether they agree to have their data used for research. All of the participants in this study had given their informed consent for research. We conducted the study in accordance with the ethical standards set forth in the Helsinki Declaration (1983). The study protocol was approved by the Angers Ethical Committee.
RESULTS
Our 43 participants had a mean age of 84.7 ± 6.3 years (range, 69.3 to 98.3 years), and 65.1% were women ( Table 1 ). The mean baseline MMSE score was 16.7 ± 4.6. The mean time between the initial and followup visits was 0.6 ± 0.4 years.
Eighteen participants received memantine alone (41.9%), 17 received vitamin D alone (39.5%), and 8 received memantine plus vitamin D (18.6%). The 3 groups had no significant differences in age (P = 0.632), sex (P = 0.592), or baseline MMSE score (P = 0.094). We found no differences in the time between visits (P = 0.155) or the season when treatment began (P = 0.275).
The only significant difference between groups was the change in MMSE score after treatment (P = 0.019). The participants taking memantine plus vitamin D had a mean increase in MMSE score of 4.0 ± 3.7 points (P = 0.034 for the comparison of mean MMSE score before and after treatment), while participants taking memantine alone remained stable at a mean of 0.0 ± 1.8 points (P = 0.891 for before and after comparison) and those taking vitamin D alone lost a mean of 0.6 ± 3.1 points (P = 0.504 for before and after comparison). Consistently, the change in MMSE score among participants taking memantine plus vitamin D was greater than the change among participants taking memantine alone (P = 0.008 for between-group comparison) or vitamin D alone (P = 0.004 for between-group comparison). There was no difference between the latter 2 groups (P = 0.356 for between-group comparison). Table 2 shows the significant benefit of memantine plus vitamin D on MMSE scores as compared to either memantine or vitamin D alone, whether the linear models were adjusted for baseline MMSE score or all clinical characteristics. Using the season of treatment start as a potential confounder did not alter the results (data not shown).
Finally, the mixed-effects regression analysis (Table 3 ) confirmed our finding by showing a significant interaction of visit by combined treatments (memantine plus vitamin D) compared to memantine or vitamin D alone.
DISCUSSION
The main finding of our study was that patients with AD who were treated for 6 months with the combination of memantine plus vitamin D supplements had a statistically and clinically significant gain in global cognitive performance. This gain was independent of age, sex, and baseline cognitive performance. By contrast, patients treated with memantine or vitamin D alone had a slight decline in cognition. These results suggest that memantine and vitamin D likely interact and potentiate each other to protect neurons and improve AD symptoms. An increasing number of drugs with multi-target effects are being developed to treat AD. 11, 12 To the best of our knowledge, our study is the first to focus on the combination of memantine plus vitamin D, although their complementary modes of action have been reported. 13 In AD, dysfunctional glutamatergic neurotransmission increases excitation of extrasynaptic NMDA receptors, allowing too much calcium to enter the postsynaptic neurons. Excessive calcium kills neurons by 2 mechanisms: either by immediate necrosis when the intraneuronal calcium flux is so high that it exceeds the storage capacity of the endoplasmic reticulum, or by delayed apoptosis when the calcium flux is only moderate but it causes oxidative stress. 28, 29 Memantine prevents the first mechanism. It binds to NMDA receptors with low affinity and rapid withdrawal kinetics, thus keeping excessive calcium from entering the neurons 13 ; however, memantine cannot prevent delayed apoptosis. This may explain why memantine can temporarily delay cognitive decline but cannot stop or reverse it. 7, 13 Vitamin D is a neurosteroid hormone that crosses the blood-brain barrier and binds to vitamin D receptors in neurons of the hippocampus, hypothalamus, cortex, and subcortex. 15 The vast majority of older adults have vitamin D insufficiency. 26 The correction of vitamin D insufficiency is justified by numerous observational crosssectional 19, [30] [31] [32] [33] [34] and longitudinal [34] [35] [36] studies reporting an association between low serum vitamin D concentrations and poor cognitive performance. Similarly, observational studies have reported an association between low dietary vitamin D intake and cognitive impairment in older women, 37 and between low dietary intake and higher risk of developing AD. 38 Although no placebo-controlled clinical trial has yet examined the effectiveness of vitamin D supplements on cognition, 18 these studies suggest that vitamin D can protect against neurodysfunction and cognitive decline.
Consistent with these findings, in vitro mouse studies have shown that vitamin D may reverse age-related inflammatory changes in the hippocampus. 39 Vitamin D may also reduce amyloid-b42 accumulation by stimulating phagocytosis of the amyloid-b peptide 40 and enhancing brain-to-blood amyloid-b efflux transport at the bloodbrain barrier, 41 thus reducing the number of amyloid plaques. 42 Importantly, vitamin D also regulates intraneuronal calcium homeostasis by regulating voltage-gated calcium channels. [43] [44] [45] In cultures of rat mesencephalic cells, vitamin D's anti-oxidant effects have protected neurons against glutamate toxicity. 46 Finally, a study of embryonic rat hippocampus showed that vitamin D may help to rebuild functional neural networks and improve cognition by regulating neurotrophic agents, mitosis, and dendritic growth in the hippocampus. 47 These neuroprotective properties could be complementary and synergistic with memantine-induced neuronal defense 13 and could explain some of our results.
Our patients' cognitive improvement after 6 months of treatment with memantine plus vitamin D may also be partly explained by mechanisms other than neuroprotection. For instance, the treatment may have restored their synaptic plasticity. In parallel with the glutamatergic overactivation of extrasynaptic NMDA receptors leading to excitotoxic cell death, 48 the continuous activation of synaptic NMDA receptors reduces synaptic plasticity (ie, long-term potentiation, which is a cellular correlate of learning and memory). [48] [49] [50] [51] The signal-to-noise ratio hypothesis assumes that magnesium, which normally acts as an endogenous NMDA receptor antagonist, cannot function properly in patients with AD because there is too much "noise" from the tonically overactive glutamatergic system. 49, 51 As an NMDA receptor antagonist that acts like an improved version of magnesium (ie, it is voltagedependent and binds to the receptor with low affinity), 49 memantine is believed to block the residual noise at the perturbed glutamatergic synapses. 50, 51 Thus, the relevant signal can be detected, meaning that synaptic plasticity has been restored, and AD symptoms are improved. Interestingly, vitamin D has also been associated with long-term potentiation. Rodent studies have shown that prenatal vitamin D deficiency alters brain development, leading to specific functional abnormalities in hippocampal synaptic plasticity, 52 in turn adversely affecting cognition and behavior. 53 This finding highlights the importance of maintaining adequate vitamin D serum concentrations and may help explain how vitamin D potentiates the effects of memantine. Because vitamin D supplements can prevent non-skeletal adverse events within the first 6 months of treatment, 54 it is reasonable to assume that the mean 6-month duration of our pre-post study captured an effect of vitamin D supplements, notably the potentiating of memantine's neuroprotective and symptomatic benefits.
We found that patients using memantine alone had stable cognitive performance after 6 months of treatment, and those using vitamin D alone experienced slight cognitive decline. Our findings are validated by their consistency with previous reports. 5, 55 Our study had some limitations. First, our 43 patients, all at a single memory clinic, may not have represented the general population of patients with AD. The study's retrospective design may have limited the number of patients who could be included. The retrospective design also prevented us from planning for the patients coming to the clinic to be treated systematically with memantine, vitamin D, or both. Although we were able to control for the main confounders, some may have eluded us. For example, the clinic did not routinely measure the patients' pre-treatment serum 25-hydroxyvitamin D concentration; a high level almost guarantees that vitamin D supplementation will not be effective (if such effects exist). 56 Another limitation of this study was the lack of a placebo group. Although including a control group would be more rigorous from a methodological point of view, it seems unethical to offer no drug to patients with AD. 57 A final limitation is that we did not consider patients with non-AD dementias such as vascular dementias.
In conclusion, we found that when patients with AD were treated with memantine plus vitamin D for 6 months, they had a statistically significant and clinically relevant 4point improvement in MMSE score. The combination was more effective than taking either drug alone. Prospective clinical trials are needed to strengthen the evidence for the effectiveness of combined memantine and vitamin D in limiting cognitive and functional decline in patients with AD and to determine the most effective doses. One such trial already in progress is our Alzheimer's Disease-Input of Vitamin D with mEmantine Assay (AD-IDEA trial) (NCT01409694 in the US National Institutes of Health database ClinicalTrials.gov), a double-blind randomized placebo-controlled parallel group intent-to-treat superiority clinical trial (for protocol, see Annweiler et al 58 ) . Elderly people may not be able to compensate for vitamin D deficiency with dietary increases or food supplements alone. 59 Further, fixed-combination agents offer benefits to patients, especially in simplifying a multidrug regimen, minimizing side effects, and maximizing compliance. 60 These observations further reinforce the potential of a single drug combining memantine with vitamin D for the management of AD.
